Jasper Therapeutics (JSPR) EBIT (2020 - 2025)

Jasper Therapeutics has reported EBIT for 6 years, with the latest figure at -$15.8 million in Q4 2025.

• On a quarterly basis, EBIT rose 37.36% year-over-year to -$15.8 million in Q4 2025; TTM through Dec 2025 was -$83.9 million, a 10.03% decrease from a year earlier, with the FY2025 full-year figure at -$83.9 million, down 10.03% from the prior year.
• EBIT was -$15.8 million for Q4 2025 at Jasper Therapeutics, up from -$19.2 million in the prior quarter.
• The five-year high for EBIT was -$6.3 million in Q1 2021, with the low at -$27.1 million in Q2 2025.
• Average EBIT over 5 years is -$15.9 million, with a median of -$15.5 million recorded in 2024.
• The sharpest annual moves came in 2021 and 2025: EBIT tumbled 2634.99% in 2021, then soared 37.36% in 2025.
• Over 5 years, EBIT stood at -$12.1 million in 2021, then dropped by 13.78% to -$13.7 million in 2022, then fell by 28.94% to -$17.7 million in 2023, then tumbled by 42.65% to -$25.3 million in 2024, then soared by 37.36% to -$15.8 million in 2025.
• The last three EBIT figures came in at -$15.8 million (Q4 2025), -$19.2 million (Q3 2025), and -$27.1 million (Q2 2025), per Business Quant data.